These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30377889)

  • 1. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.
    Biliouris K; Nestorov I; Naik H; Dai D; Xiao G; Wang Q; Pellerin A; Rabah D; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):817-827. PubMed ID: 30377889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus.
    Hartmann S; Biliouris K; Naik H; Rabah D; Stevenson L; Shen C; Nestorov IA; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):255-266. PubMed ID: 32335844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
    Furie R; Werth VP; Merola JF; Stevenson L; Reynolds TL; Naik H; Wang W; Christmann R; Gardet A; Pellerin A; Hamann S; Auluck P; Barbey C; Gulati P; Rabah D; Franchimont N
    J Clin Invest; 2019 Mar; 129(3):1359-1371. PubMed ID: 30645203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.
    Pellerin A; Otero K; Czerkowicz JM; Kerns HM; Shapiro RI; Ranger AM; Otipoby KL; Taylor FR; Cameron TO; Viney JL; Rabah D
    EMBO Mol Med; 2015 Apr; 7(4):464-76. PubMed ID: 25762615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of
    Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
    Front Immunol; 2019; 10():275. PubMed ID: 30846987
    [No Abstract]   [Full Text] [Related]  

  • 6. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
    Werth VP; Furie RA; Romero-Diaz J; Navarra S; Kalunian K; van Vollenhoven RF; Nyberg F; Kaffenberger BH; Sheikh SZ; Radunovic G; Huang X; Clark G; Carroll H; Naik H; Gaudreault F; Meyers A; Barbey C; Musselli C; Franchimont N;
    N Engl J Med; 2022 Jul; 387(4):321-331. PubMed ID: 35939578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic.
    Lledo-Garcia R; Dixon K; Shock A; Oliver R
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):116-128. PubMed ID: 34735735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
    Furie RA; van Vollenhoven RF; Kalunian K; Navarra S; Romero-Diaz J; Werth VP; Huang X; Clark G; Carroll H; Meyers A; Musselli C; Barbey C; Franchimont N;
    N Engl J Med; 2022 Sep; 387(10):894-904. PubMed ID: 36069871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
    Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
    Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.
    Titze MI; Schaaf O; Hofmann MH; Sanderson MP; Zahn SK; Quant J; Lehr T
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):545-558. PubMed ID: 28243682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Characterization of ASP2713, a Novel Igβ and FcγRIIB Cross-Linking Antibody, for Prediction of Human Pharmacokinetics and Clinically Effective Dose.
    Konishi K; Nakamura K; Hanada Y; Kitanaga Y; Kubo S; Kinugasa F; Yamajuku D; Maeda M; Yamamoto N; Minematsu T; Ohbuchi M; Kondo Y; Sumida T
    J Pharm Sci; 2022 Sep; 111(9):2630-2638. PubMed ID: 35700799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
    Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
    AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
    Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
    J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.
    Dudal S; Subramanian K; Flandre T; Law WS; Lowe PJ; Skerjanec A; Genin JC; Duval M; Piequet A; Cordier A; Jarai G; Van Heeke G; Taplin S; Krantz C; Jones S; Warren AP; Brennan FR; Sims J; Lloyd P
    MAbs; 2015; 7(5):829-37. PubMed ID: 26230385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.
    Vugmeyster Y; Rohde C; Perreault M; Gimeno RE; Singh P
    MAbs; 2013; 5(3):373-83. PubMed ID: 23529133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
    McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
    Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
    Yuan D; Rode F; Cao Y
    Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.